Washington, D.C. 20549

Form 6-K


For the month of February 2018

Commission File Number: 333-219066

Clementia Pharmaceuticals Inc.
(Translation of registrant's name into English)

4150 St Catherine Street West, Suite 550
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR. 

On February 28, 2018, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

(c) Exhibit 99.1. Press release dated February 28, 2018


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

      Clementia Pharmaceuticals Inc.    
Date: February 28, 2018     /s/ MICHAEL SINGER    
  Michael Singer
  Chief Financial Officer


Clementia Reports 2017 Operating Results and Business Highlights

Enrollment Underway in Palovarotene Phase 3 MOVE Trial for Fibrodysplasia Ossificans Progressiva (FOP)

On-track to Enroll First Patient in Palovarotene Phase 2 MO-Ped Trial for Multiple Osteochondromas (MO) this Quarter

MONTREAL, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ:CMTA), a clinical-stage biopharmaceutical company innovating new treatments for people with ultra-rare bone disorders and other diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2017 and provided an update on recent corporate and clinical developments.

“Since our transition into a publicly traded company last August, we made significant progress with our palovarotene clinical programs, which have the opportunity to be the first treatments in two rare and severely disabling bone disorders,” commented Clarissa Desjardins, Ph.D., chief executive officer of Clementia. “The initiation of the Phase 3 MOVE Trial marks the first-ever registration study for the treatment of individuals with FOP, and we are on-track to initiate enrollment in the first-ever clinical trial in individuals with MO in the first quarter. These studies represent critical steps forward for Clementia and our transformation into a late-stage company that plans to bring our products to market ourselves. Palovarotene has the potential to change the way individuals with these debilitating bone disorders are treated, and we will continue working closely with patients and investigators around the world to advance these important studies.”

Recent Corporate Highlights

Upcoming Milestones

Fourth Quarter and Year End 2017 Financial Results (all amounts are presented in U.S. dollars)

About Clementia Pharmaceuticals Inc.

Clementia is a clinical-stage biopharmaceutical company innovating new treatments for people with ultra-rare bone disorders and other diseases with high medical need. The company’s lead candidate, palovarotene, a novel RARγ agonist, is currently being evaluated in the Phase 3 MOVE Trial to treat fibrodysplasia ossificans progressiva (FOP), with additional clinical studies planned in multiple osteochondromas (MO, also known as hereditary multiple exostoses) and other diseases. For more information, please visit www.clementiapharma.com.

Cautionary Note Regarding Forward-Looking Statements

This press release may include “forward-looking statements” within the meaning of the applicable securities laws. Each forward-looking statement contained in this press release is subject to known and unknown risks and uncertainties and other unknown factors that could cause actual results to differ materially from historical results and those expressed or implied by such statement. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “will,” or “plans” to be uncertain and forward-looking. Applicable risks and uncertainties include, among others, our ability to generate revenue and become profitable; the risks related to our heavy reliance on palovarotene, our only current product candidate; the risks associated with the development of palovarotene and any future product candidate, including the demonstration of efficacy and safety; our heavy dependence on licensed intellectual property, including our ability to source and maintain licenses from third-party owners; as well as the risks identified under the heading “Risk Factors” in our Annual Report on Form 20-F filed with the Securities and Exchange Commission (“SEC”), as well as the other information we file with the SEC or on SEDAR.  We caution investors not to rely on the forward-looking statements contained in this press release when making an investment decision in our securities.  You are encouraged to read our filings with the SEC or on SEDAR, available at www.sec.gov or www.sedar.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this press release, and we undertake no obligation to update or revise any of these statements, whether as a result of new information, future events or otherwise, except as required by law.

Investor/Media Contact:
Joseph Walewicz
Clementia Pharmaceuticals Inc.

Chelcie Lister
THRUST Investor Relations

Clementia Pharmaceuticals Inc.
Consolidated Statements of Financial Position (unaudited)
As at
(in US dollars)
December 31,
 December 31,
Current assets  
Cash   $36,230,343 $9,434,495 
Short-term investments30,000,000 30,000,000 
Interest receivable575,499 307,579 
Sales tax and other receivables94,497 90,966 
Income tax and tax credits receivable977,901 139,223 
Prepaid expenses3,798,882 652,158 
Total current assets71,677,122 40,624,421 
Non-current assets  
Long-term investments75,000,000 - 
Property and equipment33,084 38,163 
Intangible assets1,715,192 894,584 
Total non-current assets76,748,276 932,747 
Total assets$148,425,398 $41,557,168 
Current liabilities  
Accounts payable and accrued liabilities$6,718,666 $4,521,537 
Income taxes payable- 2,176 
Total current liabilities6,718,666 4,523,713 
Non-current liabilities  
Preferred shares- 67,880,952 
Embedded derivatives- 117,824,611 
Total non-current liabilities- 185,705,563 
Total liabilities$6,718,666 190,229,276 
Common shares230,659,692 272,391 
Contributed surplus2,659,348 498,471 
Total equity141,706,732 (148,672,108)
Total equity and liabilities$148,425,398 $41,557,168 

Clementia Pharmaceuticals Inc.
Consolidated Statements of Net Loss and Comprehensive Loss (unaudited)
 Year ended Year ended Year ended 
 December 31, December 31, December 31, 
(in US dollars)2017 2016 2015 
Research and development expenses$27,405,648 $16,851,974 $14,396,563 
Tax credits(1,237,028)(139,212)(165,124)
 26,168,620 16,712,762 14,231,439 
General and administrative expenses9,287,036 3,405,615 5,478,833 
Interest income(1,082,030)(398,559)(109,670)
Financial expenses 80,437,802 37,645,707 56,140,121 
Net loss before income taxes114,811,428 57,365,525 75,740,723 
Income tax expense643,765 146,454 156,220 
Net loss and comprehensive loss($115,455,193)($57,511,979)($75,896,943)
Basic and diluted loss per share($7.93)($24.46)($33.06)
Weighted average number of outstanding basic and diluted shares14,560,482 2,351,347 2,295,402 

Clementia Pharmaceuticals Inc.
Consolidated Statements of Cash Flows (unaudited)

(in US dollars)
Year ended
December 31,
 Year ended
December 31,
 Year ended
December 31,
Operating activities   
Net loss($115,455,193)($57,511,979)($75,896,943)
Adjusting items   
Interest income recognized in net loss(1,082,030)(398,559)(109,670)
Depreciation of property and equipment25,297 35,055 14,506 
Amortization of intangible assets179,392 137,526 134,258 
Transaction costs recognized in net loss35,175 - 819,271 
Embedded derivative loss recognized in net loss77,902,663   33,982,042 52,563,759 
Accretion of preferred shares2,479,162 3,742,178 2,378,992 
Share-based compensation2,180,915 174,419 164,456 
Net foreign exchange (gain) loss (40,913)(82,589)382,982 
Income tax expense recognized in net loss643,765 146,454 156,220 
Income taxes paid(392,620)(98,218)(296,630)
Tax credit(330,000)- - 
Net changes in working capital   
Sales tax and other receivables3,641 (48,207)24,435 
Income tax and tax credits receivable(761,999)238,690 (85,360)
Prepaid expenses(3,146,724)350,129 65,757 
Accounts payable and accrued liabilities2,193,009 504,976 2,060,688 
Net operating cash flows(35,566,460)(18,828,083)(17,623,279)
Investing activities   
Interest income received814,110 95,526 105,124 
Acquisition of short-term investments(134,000,000)(40,000,000)(40,000,000)
Maturity of short-term investments59,000,000 10,000,000 40,000,000 
Acquisition of property and equipment(20,218)(27,918)(48,855)
Acquisition of intangible assets(1,000,000)- (116,276)
Net investing cash flows(75,206,108)(29,932,392)(60,007)
Financing activities   
Issuance of common shares31,588 - 50,256 
Proceeds of IPO137,865,000 - - 
Issuance costs – IPO(10,236,593)- - 
Issuance of Preferred Shares10,000,080 - 73,182,730 
Issuance costs – Preferred Shares(129,520)- (2,561,518)
Net financing cash flows137,530,555 - 70,671,468 
Net (decrease) increase in cash26,757,987 (48,760,475)52,988,182 
Cash, beginning of year9,434,495 58,106,885 5,503,938 
Effect of exchange rate fluctuations on cash held37,861 88,085 (385,235)
Cash, end of year$36,230,343 $9,434,495 $58,106,885